Perrigo reports Q1 adjusted EPS 60c, consensus 57c

Reports Q1 revenue $1.04B, consensus $1.09B. President and CEO Patrick Lockwood-Taylor commented, “We advanced our ‘Three-S’ Plan to Stabilize, Streamline, and Strengthen Perrigo (PRGO) as Stabilization and recovery efforts in our infant formula business led to net sales growth in the Nutrition category of 16%. Excluding the prior year benefit from retailer stocking due to the launch of Opill(R), our global brands delivered organic growth of +5.9% driven by actions to Streamline the portfolio and Strengthen investments on key brands with the highest return on investment opportunities. Investments and innovations to Strengthen the business through our ‘High-Grow’ brands remain on track to derive benefits in 2026. Collectively, the team delivered meaningful adjusted EPS growth and margin expansion versus the prior year.”